MK-5684 vs. Abiraterone or Enzalutamide in pts w/mCRPC

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

For More Information:

https://clinicaltrials.gov/study/NCT06136624?term=A%20Phase%203%20Randomized,%20Open-label%20Study%20of%20MK-5684%20Versus%20Alternative%20Abiraterone%20Acetate%20or%20Enzalutamide%20in%20Participants%20With%20Metastatic%20Castration-resistant%20Prostate%20Cancer%20(mCRPC)%20Previously%20Treated%20With%20Next-generation%20Hormonal%20Agent%20(NHA)%20and%20Taxane-based%20Chemotherapy&rank=1